^
Association details:
Biomarker:PCSK9 underexpression
Cancer:Bladder Cancer
Drug Class:Immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

NG12 - From cholesterol regulation to tumor suppression: Pcsk9 as a novel target for cancer immunotherapy

Published date:
03/10/2021
Excerpt:
TCGA analyses demonstrated that low expression of Pcsk9 predicted a significantly prolonged overall survival in nine malignancies including liver hepatocellular carcinoma (LIHC), pancreatic adenocarcinoma (PAAD), skin cutaneous melanoma (SKCM), uveal melanoma (UVM), bladder urothelial carcinoma (BLCA), lung adenocarcinoma (LUAD), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), and ovarian carcinoma (OV).